Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology · 2012 · 742 citations

Medicine, Oncology, Pharmacology +16

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

Nancy U. Lin, Véronique Dièras, Devchand Paul et al. · Clinical Cancer Research · 2009 · 663 citations · Full text

Medicine, Oncology, Breast Oncology +15

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier

Hans‐Joachim Stemmler, Manfred Schmitt, Amina Willems et al. · Anti-Cancer Drugs · 2006 · 411 citations

Medicine, Oncology, Pharmacology +17

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

Tanja Fehm, Volkmar Müller, Bahriye Aktas et al. · Breast Cancer Research and Treatment · 2010 · 357 citations

Medicine, Cancer Biology, Oncology +16